Byetta Shortage Is Bygone Era
This article was originally published in The Pink Sheet Daily
Executive Summary
After backfilling the supply channel using contract manufacturers, Lilly/Amylin resume promotions for the injectable type 2 diabetes product.
You may also be interested in...
Amylin To Celebrate New Year With New Byetta Claim For Use With TZDs
Phase III monotherapy data are expected in late 2007, partner Lilly tells “The Pink Sheet” DAILY.
Amylin To Celebrate New Year With New Byetta Claim For Use With TZDs
Phase III monotherapy data are expected in late 2007, partner Lilly tells “The Pink Sheet” DAILY.
Byetta Gains European Approval
Lilly also pursuing diabetes treatment as monotherapy and in combination with thiazolidinediones in the U.S.